The Efficacy and Safety of IBI363 in Solid Tumors

"IBI363 is based on the 3+3 model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W."

"IBI363 is based on the 3+3 model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W."

"IBI363 is based on the 3+3 model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD."

"IBI363 is based on the 3+3 model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD."

The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).